Key takeaways
When you stop Mounjaro (tirzepatide), your appetite will likely return and weight regain is common.
Stopping Mounjaro means side effects will likely subside, though timing depends on your dosage.
Do not stop taking Mounjaro without first speaking with a healthcare provider, as blood sugar spikes and other health changes may occur.
Here's what we'll cover
Key takeaways
When you stop Mounjaro (tirzepatide), your appetite will likely return and weight regain is common.
Stopping Mounjaro means side effects will likely subside, though timing depends on your dosage.
Do not stop taking Mounjaro without first speaking with a healthcare provider, as blood sugar spikes and other health changes may occur.
Mounjaro (tirzepatide) is a medication approved to help control blood sugar in people with type 2 diabetes and is often prescribed off-label for weight loss. If you are taking Mounjaro and considering stopping, you may be wondering what happens when you stop taking it.
While Mounjaro is not associated with classic withdrawal symptoms, you may notice increased appetite, weight gain, or blood sugar spikes when you stop taking it.
4 things that can happen when you stop taking Mounjaro
Because Mounjaro is relatively new, limited research currently exists on what specifically happens when you stop taking it. It can take four weeks or more to see the health benefits of Mounjaro, so a healthcare provider may recommend giving it adequate time before discontinuing.
If you experience a severe reaction to Mounjaro, seek emergency medical attention. As with any prescription medication, a healthcare provider should be consulted before stopping use on your own. Let your prescribing provider know if your Mounjaro was discontinued by a different healthcare provider. Based on the available research and compared with similar medications like Ozempic (semaglutide), here are possible changes to expect when stopping Mounjaro.
Increased appetite
Part of the reason Mounjaro is effective for weight loss is that it reduces appetite. Mounjaro achieves this in part by slowing the movement of food through the digestive system, which promotes a feeling of fullness.
When you stop Mounjaro, appetite will likely return. Being aware of this in advance may help with planning strategies to manage hunger. Keeping healthy snacks on hand or eating smaller, more frequent meals may help with satiety.
Weight gain
Mounjaro is approved by the US Food and Drug Administration (FDA) to help control blood sugar in people with type 2 diabetes, but research suggests it is also effective for weight loss. One study found that at the highest dose of Mounjaro, more than half of participants lost over 20% of their body weight after 72 weeks. Research suggests it may be easier to regain weight than to lose it initially.
Stopping Mounjaro does carry a risk of weight regain. Pairing diabetes treatment with healthy habits — such as a nutrient-rich eating plan and regular exercise — may help support long-term weight management. If weight regain occurs after stopping Mounjaro, continuing with established healthy habits may help limit it.
Blood sugar changes
Mounjaro acts on GIP and GLP-1 receptors, which helps the body manage glucose more efficiently. Because it works to lower blood sugar, stopping Mounjaro may carry a risk of glucose levels rising back toward pre-treatment levels.
Because Mounjaro also reduces appetite, stopping it may lead to increased food intake — including foods that may affect blood sugar levels — which could further contribute to rising blood sugar levels.
No more side effects
Most prescription medications carry a risk of side effects. Common side effects of Mounjaro include indigestion, abdominal discomfort, diarrhea, nausea, and vomiting.
Not everyone will experience side effects or adverse reactions to Mounjaro. For those who do, one benefit of stopping the medication is that side effects will likely resolve. Depending on the dosage, it may take a few weeks for side effects to fully subside.
Do the side effects of Mounjaro go away after stopping?
Stopping Mounjaro means any side effects experienced on the medication will likely cease.
How long it takes for side effects to resolve depends on the dosage. For example, at the maximum dosage of 15 mg, it may take weeks for side effects to taper off. If the medication is discontinued at a dosage of 2.5 mg, side effects may resolve in a slightly shorter time frame.
Individual responses to medication vary, so biology also influences how quickly the body clears Mounjaro after stopping. Those who experienced moderate to severe reactions on Mounjaro may take longer to feel back to normal compared with those who had mild side effects.
How to keep the weight off after Mounjaro
As with stopping any weight loss medication, maintaining a consistent eating plan and exercise routine may support long-term weight management. Mounjaro tends to be most effective when used alongside healthy lifestyle habits.
Those struggling to maintain weight loss after stopping Mounjaro may benefit from working with a registered dietitian to develop a sustainable eating plan. A personal trainer or fitness coach may also be helpful for those with the budget. Leaning on a gym partner or social support network can also provide encouragement toward long-term health goals.
Drinking water instead of sugar-laden beverages and eating smaller, more frequent meals are practical strategies for managing appetite and calorie intake after stopping Mounjaro.
Depending on why Mounjaro was stopped, another option may be trying a different weight loss medication. Not all weight loss medications share the same side effect profile, and alternatives such as Wegovy (semaglutide) or Zepbound (tirzepatide) may be worth discussing with a healthcare provider.
When should you stop Mounjaro?
Stopping Mounjaro without speaking with a healthcare provider first is not recommended. However, there are some cases where stopping immediately is warranted.
According to the manufacturer, signs of pancreatitis — such as severe, persistent abdominal pain that may radiate to the back — warrant stopping Mounjaro. Signs of a serious allergic reaction, such as swelling of the face, tongue, or throat, difficulty breathing, or a severe rash, also warrant stopping the medication and seeking immediate medical attention.
Those experiencing severe nausea, vomiting, or diarrhea should seek medical attention, as dehydration from these symptoms may lead to kidney injury. Those taking Mounjaro who experience low blood sugar should contact a healthcare provider, who may recommend discontinuing Mounjaro or adjusting the dosage of Mounjaro or other medications.
How to stop taking Mounjaro safely
Working alongside a healthcare provider is recommended when stopping Mounjaro. Depending on the reason for stopping the medication, a healthcare provider may recommend gradually reducing the dose to give the body time to adjust and minimize abrupt changes in blood sugar or appetite.
A healthcare provider can also discuss alternative medications — such as another GLP-1 receptor agonist or metformin — if ongoing help managing blood sugar or weight is needed. Some people choose to set weight or blood sugar benchmarks that, when crossed, signal it may be time to restart treatment.
Bottom line
Here are a few key things to keep in mind about stopping Mounjaro.
Stopping Mounjaro is a decision best made alongside a healthcare provider, who can help with safely tapering the medication and planning next steps.
Mounjaro is not associated with classic withdrawal symptoms; however, stopping the medication may cause appetite to return, weight to increase, and blood sugar levels to rise.
Because both diabetes and obesity are chronic conditions, many people find they need to stay on Mounjaro long-term — or transition to another medication — to maintain results. In some cases, symptoms may be manageable with lifestyle changes alone though blood sugar and weight should be monitored closely.
Frequently asked questions (FAQs)
What is Mounjaro?
Mounjaro (tirzepatide) is a prescription medication approved in combination with diet and exercise to help control blood sugar in adults with type 2 diabetes. Tirzepatide is also FDA-approved for chronic weight management under the brand name Zepbound. When prescribed as Mounjaro for people without type 2 diabetes, it would be considered off-label use for weight loss. Mounjaro tends to be most effective when used alongside exercise and a healthy eating plan.
The US Food and Drug Administration (FDA) first approved Mounjaro in May 2022. Mounjaro is considered a first-in-class medication because it activates glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, hormones responsible for controlling blood sugar and regulating appetite and metabolism.
Mounjaro works by enhancing glucose-dependent insulin secretion and reducing glucagon secretion from the pancreas, which allows the body to use blood sugar more effectively. Because Mounjaro also delays the emptying of food from the stomach, it may promote a feeling of fullness and decrease food intake, which can contribute to weight loss in some people.
Mounjaro differs from other injectable diabetes medications such as Ozempic (a GLP-1 receptor agonist) in that it acts on two receptors, which is why it is referred to as a dual agonist or combination medication. Mounjaro is given as a subcutaneous (under the skin) injection once weekly. Dosages start at 2.5 mg and are gradually increased as needed to a maximum dosage of 15 mg.
Do you have to stay on Mounjaro forever?
Mounjaro is used to treat type 2 diabetes and obesity, both of which are chronic conditions, meaning symptoms may return when the medication is stopped. Many people choose to stay on Mounjaro long-term to maintain blood sugar control and weight management. The decision to continue, adjust, or stop Mounjaro should be made with a healthcare provider based on your individual health goals, treatment response, and other factors.
How to successfully come off Mounjaro?
Working with a healthcare provider to develop a plan for stopping Mounjaro is recommended. Rather than stopping the medication abruptly, a healthcare provider may recommend a a tapering schedule, which could help you reduce the risk of weight regain and blood sugar increases.
What are the side effects of coming off of Mounjaro?
Mounjaro is not associated with classic withdrawal symptoms; however, stopping the medication may result in increased appetite, blood sugar increases, and weight regain.
Will you gain weight after stopping Mounjaro?
Weight regain is common after stopping Mounjaro. Clinical trials found that 82.5% of participants who stopped tirzepatide regained at least 25% of the weight they had lost within a year. Maintaining healthy habits and working toward more than 60 minutes of physical activity per day may help limit weight regain.
What are the side effects of Mounjaro?
Potential side effects of Mounjaro include:
Abdominal pain
Constipation
Diarrhea
Indigestion
Nausea and vomiting
Decreased appetite
For a more comprehensive list of side effects, read the FDA label.
DISCLAIMER
If you have any medical questions or concerns, please talk to your healthcare provider. The articles on Health Guide are underpinned by peer-reviewed research and information drawn from medical societies and governmental agencies. However, they are not a substitute for professional medical advice, diagnosis, or treatment.
Mounjaro Important Safety Information: Read more about serious warnings and safety info.
Ozempic Important Safety Information: Read more about serious warnings and safety info.
GLP-1 Important Safety Information: Read more about serious warnings and safety info.
Wegovy Important Safety Information: Read more about serious warnings and safety info.
Zepbound Important Safety Information: Read more about serious warnings and safety info.
References
Ali, R., Virendra, S. A., & Chawla, P. A. (2022). Bumps and humps in the success of Tirzepatide as the first GLP1 and GIP receptor agonist. Health Sciences Review, 4, 100032. doi: 10.1016/j.hsr.2022.100032. Retrieved from https://www.sciencedirect.com/science/article/pii/S2772632022000216
Centers for Disease Control and Prevention (CDC). (2023). Adult activity: An overview. Physical Activity Basics. Retrieved from https://www.cdc.gov/physical-activity-basics/guidelines/adults.html
Chang, T., Ravi, N., Plegue, M. A., et al. (2016). Inadequate Hydration, BMI, and Obesity Among US Adults: NHANES 2009–2012. Annals of Family Medicine, 14(4) 320-324. doi: 10.1370/afm.1951. Retrieved from https://www.annfammed.org/content/14/4/320.full
Chavda, V. P., Ajabiya, J., Teli, D., et al. (2022). Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. Molecules, 27(13), 4315. doi: 10.3390/molecules27134315. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9268041/
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. The New England Journal of Medicine, 387(3), 205-216. doi: 10.1056/NEJMoa2206038. Retrieved from https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
Mounjaro. (2023). Once-weekly Mounjaro comes in a single-dose pen. Retrieved from https://www.mounjaro.com/how-to-use-mounjaro#how-to-use
Rodriguez, P. J., Goodwin Cartwright, B. M., Gratzl, S., et al. (2024). Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity. JAMA Internal Medicine, 184(9), 1056–1064. doi: 10.1001/jamainternmed.2024.2525. Retrieved from https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2841273
Thomas, M. K., Nikooienejad, A., Bray, R., et al. (2021). Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism, 106(2), 388–396. doi: 10.1210/clinem/dgaa863. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823251/
U.S. Food and Drug Administration (FDA-a). (2022). FDA Approves Novel, Dual-Targeted Treatment for Type 2 Diabetes. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-novel-dual-targeted-treatment-type-2-diabetes
U.S. Food and Drug Administration (FDA-b). (2022). MOUNJARO (tirzepatide) Injection, for subcutaneous use. Retrieved from https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/d2d7da5d-ad07-4228-955f-cf7e355c8cc0/spl-doc?hl=mounjaro














